The following is a message from the Director of the FDA Oncology Center of Excellence, Dr. Richard Pazdur: On February 11, 2025, the Food and Drug Administration approved brentuximab vedotin (Adcetris ...
ALEXANDRIA, Va. – Nine studies exploring new approaches for the treatment of genitourinary cancers will be presented at the upcoming 2025 American Society of Clinical Oncology (ASCO) Genitourinary ...
“The TALAPRO-2 study showed a significant improvement in overall survival in men with mCRPC treated with the combination of talazoparib and enzalutamide whether they had HRR gene alterations. In this ...
Study phase and tumor characteristics of patients with GBM or G4 astrocytoma Number of patients treated with 15–30 mg/day lisavanbulin Number of patients with Objective response Best response and ...
Development and validation of a prognostic score for overall survival integrating baseline metabolically active tumor volume measured by 18 F-FDG PET/CT and clinical factors for metastatic colorectal ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
To learn more about the Oncology Medical Home standards and ASCO Certified recognition from ASCO, please click the button below and submit your questions. ASCO Certified has launched a new application ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback